Mechanism of Brd4-mediated papillomavirus host interactions

Brd4介导的乳头瘤病毒宿主相互作用的机制

基本信息

  • 批准号:
    8598663
  • 负责人:
  • 金额:
    $ 5.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-02-18 至 2014-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): High-risk human papillomavirus (HPV) infection is the primary risk factor for cervical cancer, which is the second most prevalent cancer in women worldwide causing 15% of female cancer mortality. Papillomaviruses establish persistent infection by maintaining their genomes as episomes in infected cells. In the HPV life cycle that is tightly linked to the differentiation program of host epithelium, E2 ensures that the viral genome is established, replicated and maintained in the early-infected basal epithelial cells. During epithelium differentiation, E2 also contributes to the tight regulation of the viral oncogene transcription to create a conducive environment for successful completion of the viral life cycle. Loss of E2 expression leads to dysregulated viral oncogene expression and has been mechanistically linked to malignant progression of HPV positive lesions. Our previous work identified the cellular protein Brd4 (bromodomain-containing protein 4) as a novel receptor for E2. Brd4-E2 interaction functions in viral episome maintenance, viral transcriptional activation and repression of the viral oncogenes. Our studies established that Brd4 is highly expressed in the basal epithelial layer, supporting its role in E2 functions during the early phase of the viral life cycle. However, little is known about how Brd4 regulates the multiple functions of E2, nor is it clear how this virus-host interaction contributes to the differentiation- dependent HPV life cycle. This grant application aims to identify and characterize additional cellular components that regulate the E2-Brd4 functions, to determine how Brd4 contributes to E2 transcriptional regulation, and to investigate the functional impact of E2-Brd4 interactions in the HPV life cycle during epithelium differentiation. Infection by the HPV is the most common sexually transmitted agent, afflicting 50-80% of the population. This research will provide greater understanding of the molecular mechanisms that regulate the HPV life cycle and malignant progression. The new mechanisms identified in this study will provide a point of departure for developing new compounds to abrogate the virus-host interaction and cure HPV persistent infections. Mechanistic insights into how E2-Brd4 interactions repress the viral oncogenes that account for the tumorigenic nature of HPV-associated diseases will offer promising leads for novel therapeutic strategies. This study will provide a paradigm for other episomal DNA tumor viruses, including Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus, both of which also target Brd4.
描述(由申请人提供):高危人乳头瘤病毒(HPV)感染是宫颈癌的主要风险因素,宫颈癌是全球女性第二大流行癌症,占女性癌症死亡率的15%。乳头瘤病毒通过将其基因组维持为感染细胞中的附加体来建立持续感染。在与宿主上皮分化程序紧密相关的HPV生命周期中,E2确保病毒基因组在早期感染的基底上皮细胞中建立、复制和维持。在上皮细胞分化过程中,E2还有助于严格调节病毒癌基因转录,为成功完成病毒生命周期创造有利环境。E2表达的缺失导致病毒癌基因表达失调,并与HPV阳性病变的恶性进展有机械联系。我们以前的工作确定了细胞蛋白Brd 4(含溴结构域蛋白4)作为一种新的E2受体。Brd 4-E2相互作用在病毒附加体维持、病毒转录激活和病毒癌基因抑制中起作用。我们的研究表明,Brd 4在基底上皮层中高度表达,支持其在病毒生命周期早期E2功能中的作用。然而,关于Brd 4如何调节E2的多种功能知之甚少,也不清楚这种病毒-宿主相互作用如何有助于分化依赖性HPV生命周期。该拨款申请旨在鉴定和表征调节E2-Brd 4功能的其他细胞成分,确定Brd 4如何促进E2转录调节,并研究上皮分化期间HPV生命周期中E2-Brd 4相互作用的功能影响。HPV感染是最常见的性传播媒介,影响50-80%的人口。这项研究将提供更好的了解调节HPV生命周期和恶性进展的分子机制。本研究中确定的新机制将为开发新化合物以消除病毒-宿主相互作用和治愈HPV持续感染提供出发点。对E2-Brd 4相互作用如何抑制病毒致癌基因的机制的深入了解将为新的治疗策略提供有希望的线索,这些病毒致癌基因是HPV相关疾病的致瘤性的原因。这项研究将为其他附加型DNA肿瘤病毒提供范例,包括卡波西肉瘤相关疱疹病毒和EB病毒,这两种病毒也靶向Brd 4。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jianxin You其他文献

Jianxin You的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jianxin You', 18)}}的其他基金

Targeting MCPyV oncogene transcription to suppress tumorigenesis
靶向 MCPyV 癌基因转录抑制肿瘤发生
  • 批准号:
    10753259
  • 财政年份:
    2023
  • 资助金额:
    $ 5.78万
  • 项目类别:
Project 3: Skin hypoxia, MCPyV infection, and MCC tumorigenesis
项目3:皮肤缺氧、MCPyV感染和MCC肿瘤发生
  • 批准号:
    10714175
  • 财政年份:
    2023
  • 资助金额:
    $ 5.78万
  • 项目类别:
A novel gene therapy approach targeting STING-silenced cold tumors
一种针对 STING 沉默冷肿瘤的新型基因治疗方法
  • 批准号:
    10577939
  • 财政年份:
    2022
  • 资助金额:
    $ 5.78万
  • 项目类别:
Overcoming the immune evasion mechanism of Merkel cell polyomavirus-associated Merkel cell carcinoma
克服默克尔细胞多瘤病毒相关默克尔细胞癌的免疫逃避机制
  • 批准号:
    9894065
  • 财政年份:
    2020
  • 资助金额:
    $ 5.78万
  • 项目类别:
Merkel cell polyomavirus infection and the host immune response
默克尔细胞多瘤病毒感染与宿主免疫反应
  • 批准号:
    10001428
  • 财政年份:
    2019
  • 资助金额:
    $ 5.78万
  • 项目类别:
Merkel cell polyomavirus infection, host response, and viral oncogenic mechanism
默克尔细胞多瘤病毒感染、宿主反应和病毒致癌机制
  • 批准号:
    10365419
  • 财政年份:
    2015
  • 资助金额:
    $ 5.78万
  • 项目类别:
Merkel cell polyomavirus infection, host response, and viral oncogenic mechanism
默克尔细胞多瘤病毒感染、宿主反应和病毒致癌机制
  • 批准号:
    10536636
  • 财政年份:
    2015
  • 资助金额:
    $ 5.78万
  • 项目类别:
Merkel cell polyomavirus infection, DNA damage response and cancer
默克尔细胞多瘤病毒感染、DNA 损伤反应与癌症
  • 批准号:
    9016508
  • 财政年份:
    2015
  • 资助金额:
    $ 5.78万
  • 项目类别:
Mechanism of Brd4-mediated papillomavirus host interactions
Brd4介导的乳头瘤病毒宿主相互作用的机制
  • 批准号:
    7765911
  • 财政年份:
    2010
  • 资助金额:
    $ 5.78万
  • 项目类别:
Chromatin structure maintenance and cancer
染色质结构维持与癌症
  • 批准号:
    8225375
  • 财政年份:
    2010
  • 资助金额:
    $ 5.78万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 5.78万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 5.78万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 5.78万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 5.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 5.78万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 5.78万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 5.78万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 5.78万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 5.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 5.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了